Portal blood flow in nonalcoholic fatty liver disease during the treatment
DOI:
https://doi.org/10.15587/2313-8416.2014.30424Keywords:
nonalcoholic fatty liver disease, hypertension, coronary heart disease, portal blood flowAbstract
The state of portal hemodynamics in non-alcoholic fatty liver disease in combination with hypertension and coronary heart disease during the treatment is investigated. Complex therapy significantly decreased the ratio of portosystemic shunt, which is a sign of decrease in portal pressure and hindered the development of portopulmonary syndrome.
References
Storozhakov, G. I., Ivkova, A. N. (2009). Patogeneticheskie aspektyi fibrogeneza pri hronicheskih zabolevaniyah pecheni (Pathogenetic aspects of fibrogenesis in chronic liver diseases). Clinical Perspectives in Gastroenterology, Hepatology, 2, 3–10.
Agafonov, A. V., Tuev, A. V., Nekrutenko, L. A., Bochkova, Yu. V. (2005). Arterialnoe remodelirovanie u bolnyih arterialnoy gipertenziey pozhilogo i starshego vozrasta (Arterial remodeling in hypertensive patients of elderly and older). Russian Cardiology Journal, 3, 25–28.
Versari, D., Daghini, E., Virdis, A. et al. (2009). Endothelium–dependent contractions and endothelial dysfunction in human hypertension. British Journal of Pharmacology, 157 (4), 527–536. doi: 10.1111/j.1476-5381.2009.00240.x
Oparil, S., Zaman, A., Calhoun, D. A. (2003). Pathogenesis of arterial hypertension. Annals of Internal Medicine, 139, 7617–7626.
Chen, J., Talwalkar, J. A., Yin, M., Glaser, K. J., Sanderson, S. O., Ehman, R. L. (2011). Early Detection of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease by Using MR Elastography. Radiology, 259 (3), 749–756. doi: 10.1148/radiol.11101942
V.W. Wong , W.C. Chu G. L.-H. Wong, R. S.-M. Chan, A. M.-L. Chim, A. Ong, D. K.-W. Yeung, K. K.-L. Yiu, S. H.-T. Chu, J. Woo, F. K.-L. Chan, H. L.-Y. Chan (2011). Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut, 61 (3), 409–415. doi: 10.1136/gutjnl-2011-300342
Thiruvagounder, M., Khan, S., Sheriff, D. S. (2010). The prevalence of metabolic syndrome in India. Biochemia Medica, 20 (2), 249–252.
Ioannou, G. N., Weiss, N. S., Boyko, E. J., Mozaffarian, D., Lee, S. P. (2006). Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology, 43 (5), 1145–1151. doi: 10.1002/hep.21171
Kozlov, O. P. (2012). Stan portalnogo krovotoku u hvorih na nealkogolnu zhirovu hvorobu pechInki (Status of portal blood flow in patients with nonalcoholic fatty liver disease). Actual problems of modern medicine: Bulletin of the Ukrainian Medical Dental Academy, 12/3 (39), 46–50.
Paschos, P., Tziomalos, K. (2012). Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment . World J. Hepatol., 4 (12), 327–331.
Yoshiji, H., Kuriyama, S., Fukui, H. (2007). Blockade of renin-angiotensin system in antifibrotic therapy. Journal of Gastroenterology and Hepatology, 22 (s1), 893–895. doi: 10.1111/j.1440-1746.2006.04663.x
Huang, M. L., Li, X., Meng, Y., Xiao, B., Ma, Q., Ying, S. S., Wu, P. S., Zhang, Z. S. (2010). Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. Clinical and Experimental Pharmacology and Physiology, 37 (1). – Р. 1–6. doi: 10.1111/j.1440-1681.2009.05302.x
Li, L., Luo, Z., Yu, H., Feng, X., Wang, P., Chen, J., Pu, Y., Zhao, Y., He, H., Zhong, J., Liu, D., Zhu, Z. (2013). Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation. Diabetes, 62 (3), 762–774. doi: 10.2337/db12-0570
Drake, J. I., Gomez-Arroyo, J., Dumur, C. I., Kraskauskas, D., Natarajan, R., Bogaard, H. J., Fawcett, P., Voelkel, N. F. (2013). Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiological Genomics, 45 (12), 449–461. doi: 10.1152/physiolgenomics.00166.2012
Hobolth, L., Bendtsen, F., Hansen, E. F. (2014). Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. Digestive and Liver Disease, 46 (3), 251–256. doi: 10.1016/j.dld.2013.10.013
Ko, S. Y., Kim, J. H., Choe, W. H., Kwon, S. Y., Lee, C. H. (2012). Pharmacotherapy alone vs endoscopic variceal ligation combination for secondary prevention of oesophageal variceal bleeding: meta-analysis. Liver International, 32 (5), 867–869. doi: 10.1111/j.1478-3231.2011.02681.x
Vize-Hripunova, M. A., Zagoranskaya, N. S., Ismailova, S. A. (2005). Effektivnost lizinoprila v korrektsii portalnoy gipertenzii u bolnyih tsirrozom pecheni (Efficacy of lisinopril in the correction of portal hypertension in patients with liver cirrhosis). Russian Journal of Gastroenterology, Hepatology and Coloproctology, 26, 69.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 Александр Петрович Козлов
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
